ZA202104594B - Formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile - Google Patents

Formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile

Info

Publication number
ZA202104594B
ZA202104594B ZA2021/04594A ZA202104594A ZA202104594B ZA 202104594 B ZA202104594 B ZA 202104594B ZA 2021/04594 A ZA2021/04594 A ZA 2021/04594A ZA 202104594 A ZA202104594 A ZA 202104594A ZA 202104594 B ZA202104594 B ZA 202104594B
Authority
ZA
South Africa
Prior art keywords
formulations
quinazolin
benzonitrile
oxo
isopropyl
Prior art date
Application number
ZA2021/04594A
Other languages
English (en)
Inventor
Muneto Mogi
Joseph Paul Bullock
Chinmay Maheshwari
Quintus Medley
Michela Montecchi-Palmer
Kalliopi Stasi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA202104594B publication Critical patent/ZA202104594B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
ZA2021/04594A 2019-02-15 2021-07-01 Formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile ZA202104594B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962806705P 2019-02-15 2019-02-15
PCT/IB2020/051211 WO2020165839A1 (en) 2019-02-15 2020-02-13 Formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile

Publications (1)

Publication Number Publication Date
ZA202104594B true ZA202104594B (en) 2024-10-30

Family

ID=69740424

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2021/04594A ZA202104594B (en) 2019-02-15 2021-07-01 Formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile

Country Status (23)

Country Link
US (4) US11478480B2 (cg-RX-API-DMAC10.html)
EP (1) EP3923912A1 (cg-RX-API-DMAC10.html)
JP (5) JP6994061B2 (cg-RX-API-DMAC10.html)
KR (2) KR20260057219A (cg-RX-API-DMAC10.html)
CN (2) CN111568906B (cg-RX-API-DMAC10.html)
AU (2) AU2020220957B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021015737A2 (cg-RX-API-DMAC10.html)
CA (1) CA3130237A1 (cg-RX-API-DMAC10.html)
CL (1) CL2021002153A1 (cg-RX-API-DMAC10.html)
CO (1) CO2021010689A2 (cg-RX-API-DMAC10.html)
CR (1) CR20210428A (cg-RX-API-DMAC10.html)
EC (1) ECSP21059628A (cg-RX-API-DMAC10.html)
IL (1) IL284628A (cg-RX-API-DMAC10.html)
JO (1) JOP20210224A1 (cg-RX-API-DMAC10.html)
MX (2) MX2021009704A (cg-RX-API-DMAC10.html)
MY (1) MY206327A (cg-RX-API-DMAC10.html)
PE (1) PE20212106A1 (cg-RX-API-DMAC10.html)
PH (1) PH12021551967A1 (cg-RX-API-DMAC10.html)
SA (1) SA521430043B1 (cg-RX-API-DMAC10.html)
SG (1) SG11202107259QA (cg-RX-API-DMAC10.html)
TW (1) TWI827800B (cg-RX-API-DMAC10.html)
WO (1) WO2020165839A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202104594B (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200261456A1 (en) * 2019-02-15 2020-08-20 Novartis Ag Methods for treating ocular surface pain
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
WO2021191273A1 (en) * 2020-03-24 2021-09-30 Hovione Scientia Limited Compositions for use in treating meibomian gland dysfunction
US12459902B2 (en) * 2020-08-06 2025-11-04 Bausch + Lomb Ireland Limited Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile and formulations thereof
TW202222298A (zh) * 2020-10-07 2022-06-16 瑞士商諾華公司 含有可溶解的眼部插入物之藥物及其使用方法
US20230159202A1 (en) * 2021-11-23 2023-05-25 Bausch + Lomb Ireland Limited Method for making a preservative-free packaged ophthalmic device product
US20240197691A1 (en) * 2022-12-15 2024-06-20 Cn2 Therapeutics, Inc. Tacrolimus compositions and methods of use
CN118340775A (zh) * 2023-01-09 2024-07-16 维眸生物科技(浙江)有限公司 一种含vvn539的眼用组合物及其用途
EP4454639A1 (en) * 2023-04-14 2024-10-30 Omnivision GmbH Ophthalmic composition comprising carbomer and taurine

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1280874B (de) 1963-10-09 1968-10-24 Boehringer Sohn Ingelheim 2-Methyl-3-(2-dimethylaminophenyl)-8-amino-3H-chinazolon-(4)
US4027020A (en) 1974-10-29 1977-05-31 Millmaster Onyx Corporation Randomly terminated capped polymers
US3931319A (en) 1974-10-29 1976-01-06 Millmaster Onyx Corporation Capped polymers
US4407791A (en) 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4525346A (en) 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4836986A (en) 1984-09-28 1989-06-06 Bausch & Lomb Incorporated Disinfecting and preserving systems and methods of use
US5037647A (en) 1988-09-15 1991-08-06 Alcon Laboratories, Inc. Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride
US5145643A (en) 1990-01-05 1992-09-08 Allergan, Inc. Nonoxidative ophthalmic compositions and methods for preserving and using same
US5300287A (en) 1992-11-04 1994-04-05 Alcon Laboratories, Inc. Polymeric antimicrobials and their use in pharmaceutical compositions
FR2749846B1 (fr) * 1996-06-17 1998-09-11 Pf Medicament Sel de methanesulfonate d'une arylpiperazine derivee de tryptamine et ses solvates pour usage pharmaceutique
DE60006262T2 (de) * 1999-09-24 2004-05-13 Alcon, Inc. Topische suspensionsformulierungen enthaltend ciprofloxacin und dexamethason
GB0412769D0 (en) * 2004-06-08 2004-07-07 Novartis Ag Organic compounds
TWI358290B (en) * 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
US20100152209A1 (en) 2005-11-04 2010-06-17 Hydra Biosciences Inc. Compounds for Modulating TRPV3 Function
GB0525069D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
GB0525068D0 (en) * 2005-12-08 2006-01-18 Novartis Ag Organic compounds
JP2009521484A (ja) 2005-12-22 2009-06-04 プロレキシーズ ファーマシューティカルズ インコーポレイテッド ３−アリール置換キナゾロンおよびその使用
TW200738232A (en) 2006-01-31 2007-10-16 Alcon Mfg Ltd Use of vanilloid receptor-1 antagonists for the prevention and treatment of glaucoma
EP1964548A1 (en) 2007-03-02 2008-09-03 Novartis AG Pharmaceutical compositions comprising a calcilytic agent
WO2008140750A1 (en) 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
WO2009007839A1 (en) * 2007-07-11 2009-01-15 Pfizer Inc. Pharmaceutical compositions and methods of treating dry eye disorders
ES2648225T3 (es) 2007-07-18 2017-12-29 Novartis Ag Combinaciones sinérgicas de antagonistas de VR-1 e inhibidores de COX-2
TW200927192A (en) 2007-11-19 2009-07-01 Alcon Res Ltd Use of TRPV1 receptor antagonists for treating dry eye and ocular pain
WO2009081222A1 (en) 2007-12-21 2009-07-02 Glenmark Pharmaceuticals, S.A. Substituted tricyclic pyridine or pyrimidine vanilloid receptor ligands
WO2009089057A1 (en) 2008-01-09 2009-07-16 Renovis, Ins. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2009090548A2 (en) 2008-01-17 2009-07-23 Glenmark Pharmaceuticals, S.A. 3-azabicyclo [3.1.0] hexane derivatives as vanilloid receptor ligands
WO2009149239A1 (en) 2008-06-04 2009-12-10 Children's Medical Center Corporation Methods of modulating angiogenesis via trpv4
WO2010023512A1 (en) 2008-08-28 2010-03-04 Matrix Laboratories Ltd. Novel vanilloid receptor modulators, process for their preparation and pharmaceutical compositions containing them
US8349852B2 (en) * 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
EP2316420B1 (en) 2009-10-22 2014-02-26 Consorzio Universitario Unifarm Topical ophthalmic composition to reduce pain
EP2377850A1 (en) 2010-03-30 2011-10-19 Pharmeste S.r.l. TRPV1 vanilloid receptor antagonists with a bicyclic portion
US8927559B2 (en) 2010-10-11 2015-01-06 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as CRTH2 antagonists
EP2694048B1 (en) * 2011-04-05 2020-10-07 Optosolve Research & Development Ltd Ophthalmic treatments
CN102659629B (zh) * 2012-02-14 2014-03-19 杭州华东医药集团新药研究院有限公司 化合物及其在制备埃罗替尼中的用途
CN102875480A (zh) 2012-04-23 2013-01-16 中国药科大学 喹唑啉酮类血管抑制剂、其制备方法及其医药用途
GB201215857D0 (en) 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
NZ630759A (en) 2013-03-15 2017-07-28 Inotek Pharmaceuticals Corp Ophthalmic formulations comprising an a1 agonist
US20150352176A1 (en) * 2014-06-06 2015-12-10 Newport Research, Inc. Oil-free and fat-free aqueous suspensions of cyclosporin
ES2951202T3 (es) 2014-07-28 2023-10-19 Sun Pharma Advanced Res Co Ltd Método para aumentar la biodisponibilidad y/o prolongar la acción oftálmica de un fármaco
LT3193835T (lt) * 2014-09-15 2018-06-11 Verona Pharma Plc Skysta inhaliuojama vaisto forma, apimanti rpl554
HUE048564T2 (hu) * 2015-01-26 2020-08-28 Bausch & Lomb Szemészeti szuszpenzió készítmény
TW201825458A (zh) 2016-09-20 2018-07-16 英商葛蘭素史克智慧財產（第二）有限公司 Ｔｒｐｖ４拮抗劑
AU2017330620A1 (en) 2016-09-20 2019-03-28 Glaxosmithkline Intellectual Property (No.2) Limited TRPV4 antagonists
JP2019532054A (ja) 2016-09-20 2019-11-07 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ Ｔｒｐｖ４拮抗薬
JP6994061B2 (ja) * 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
US20200261456A1 (en) 2019-02-15 2020-08-20 Novartis Ag Methods for treating ocular surface pain

Also Published As

Publication number Publication date
JOP20210224A1 (ar) 2023-01-30
ECSP21059628A (es) 2021-09-30
AU2020220957B2 (en) 2023-04-06
MY206327A (en) 2024-12-11
MX2024002989A (es) 2024-03-27
CN111568906B (zh) 2023-09-01
JP7860054B2 (ja) 2026-05-15
JP7465453B2 (ja) 2024-04-11
JP2022017260A (ja) 2022-01-25
EP3923912A1 (en) 2021-12-22
CR20210428A (es) 2021-09-22
JP6994061B2 (ja) 2022-01-14
US11478480B2 (en) 2022-10-25
US20260034132A1 (en) 2026-02-05
TWI827800B (zh) 2024-01-01
JP2024095674A (ja) 2024-07-10
JP2020132634A (ja) 2020-08-31
TW202045178A (zh) 2020-12-16
US20200261457A1 (en) 2020-08-20
US12290517B2 (en) 2025-05-06
SA521430043B1 (ar) 2022-11-20
CA3130237A1 (en) 2020-08-20
CL2021002153A1 (es) 2022-04-18
MX2021009704A (es) 2021-09-14
US20200390767A1 (en) 2020-12-17
JP2022520795A (ja) 2022-04-01
KR20210127197A (ko) 2021-10-21
PH12021551967A1 (en) 2022-05-23
AU2020220957A1 (en) 2021-08-05
BR112021015737A2 (pt) 2021-10-26
IL284628A (en) 2021-08-31
AU2023203933B2 (en) 2025-06-12
CN117752662A (zh) 2024-03-26
AU2023203933A1 (en) 2023-07-13
US20230139170A1 (en) 2023-05-04
WO2020165839A1 (en) 2020-08-20
SG11202107259QA (en) 2021-08-30
WO2020165839A9 (en) 2021-03-18
PE20212106A1 (es) 2021-11-04
CN111568906A (zh) 2020-08-25
JP2024037806A (ja) 2024-03-19
KR20260057219A (ko) 2026-04-27
CO2021010689A2 (es) 2021-08-30

Similar Documents

Publication Publication Date Title
JOP20210224A1 (ar) صياغات من المركب 4-(7- هيدروكسي-2- أيزوبروبيل-4- أوكسو-4h- كوينازولين-3- يل)- بنزونيتريل
EP4338804A3 (en) Epinephrine spray formulations
TN2019000136A1 (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
EA202092086A1 (ru) Ингибиторы аргиназы
CL2021001956A1 (es) Formulaciones de inmunoconjugado anti-cd79b estables. (divisional solicitud 202002624)
MX2020009235A (es) Formulacion oftalmica.
MX2025000353A (es) Metodos para tratar el dolor de la superficie ocular
MX2025002145A (es) Tratamiento del temblor esencial usando (r)-2-(4- isopropilfenil)-n-(1-(5-(2,2,2-trifluoroetoxi)piridin-2- il)etil)acetamida
EA202092084A1 (ru) Соединения - агонисты фактора роста и дифференцировки 15 и способы их применения
JOP20210158A1 (ar) مُعَدِّلات التعبير الجيني عن hsd17b13
EA201891377A1 (ru) ПРИМЕНЕНИЕ МОДУЛЯТОРОВ КАНАЛОВ Kv3.1/Kv3.2/Kv3.3 ДЛЯ ЛЕЧЕНИЯ БОЛИ
SA519410324B1 (ar) صياغات رش إيبينيفرين
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
EA202192047A1 (ru) Соединения и их применение
EA201892098A1 (ru) Соединение, обладающее ингибирующей мутантную idh активностью, способ его получения и применения
MX2025015454A (es) Formulaciones/composiciones que comprenden ibrutinib
EA202091736A1 (ru) Применение колхицина для ингибирования роста опухоли и метастазов
EA202193285A1 (ru) Состав с модифицированным высвобождением соединения пиримидиниламинопиразола и способы лечения
MX2022000349A (es) Cardioterápico.
EA202190891A1 (ru) Композиции и способы для контролируемой стимуляции яичников
EA202192418A1 (ru) Способы лечения al-амилоидоза
EA202191927A1 (ru) Модуляторы gpr35
EA202190523A1 (ru) Замещенные индолы и способы их применения
EA201992604A1 (ru) Полинуклеотиды aadc для лечения болезни паркинсона
EA201990712A1 (ru) Лечение рассеянного склероза посредством chs-131